Hedgehog Signaling Regulates Epithelial-Mesenchymal Transition During Biliary Fibrosis in Rodents and Humans
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Study Design to Validate Biomarkers of Therapeutic Response in NASH Due to Cirrhosis
Study Design to Validate Biomarkers of Therapeutic Response in NASH Due to Cirrhosis Detlef Schuppan Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center Mainz, Germany Division of Gastroenterology, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, USA International Workshop on NASH Biomarkers, Washington, DC, May 18-19, 2018 HARVARD Research MEDICAL Center for SCHOOL Institute for Translational Immunology Immune Therapy No Conflict of Interest to Declare Related to this Presentation Fibrosis Progression and Reversal in NASH Inflammation, the reparative response and evolution of fibrosis/cirrhosis in NASH Fibrogenesis • is a waxing and waning process A • follows inflammation (reparative response) inflammation fibrosis Severity Time B Severity Time Antifibrotic therapy C cirrhosis Severity Time Schuppan et al, J Hepatol 2018 Fibrogenesis in NASH Ox. stress, ROS normal liver macrophage Insulin resistance, FFA Toxins repetitive damage MF Toxic bile salts (multiple hits) T (Auto-) Immunity HBV, HCV genetic Microbiome, nutrients quiescent predisposition stellate cell (lipoapoptotic) hepatocytes activated cholangiocytes endothelium fibrotic liver portal or collagen- Cirrhosis perivascular synthesis fibroblast organ MMP-1/3/13 failure activated matrix accumulation myofibroblast TIMP-1 Cirrhosis and HCC HSC TIMP-2 Schuppan and Afdhal, Lancet 2008 common pathways & Schuppan and Kim, JCI 2013 immune environment ! Inhibition of fibrogenesis - induction of fibrolysis normal -
Outcome Measures in Coeliac Disease Trials
Downloaded from http://gut.bmj.com/ on March 30, 2018 - Published by group.bmj.com Gut Online First, published on February 13, 2018 as 10.1136/gutjnl-2017-314853 Coeliac disease ORIGINAL ARTICLE Outcome measures in coeliac disease trials: the Tampere recommendations Jonas F Ludvigsson,1,2 Carolina Ciacci,3 Peter HR Green,4 Katri Kaukinen,5,6 Ilma R Korponay-Szabo,7,8 Kalle Kurppa,9,10 Joseph A Murray,11 Knut Erik Aslaksen Lundin,12,13 Markku J Maki,14,15 Alina Popp,16,17 Norelle R Reilly,18,19 Alfonso Rodriguez-Herrera,20 David S Sanders,21 Detlef Schuppan,22,23 Sarah Sleet,24 Juha Taavela,25 Kristin Voorhees,26 Marjorie M Walker,27 Daniel A Leffler28 ► Additional material is ABSTRact published online only. To view, Objective A gluten-free diet is the only treatment Significance of this study please visit the journal online option of coeliac disease, but recently an increasing (http:// dx. doi. org/ 10. 1136/ What is already known about this subject? gutjnl- 2017- 314853). number of trials have begun to explore alternative treatment strategies. We aimed to review the literature ► A gluten-free diet is the only treatment option For numbered affiliations see of coeliac disease, but recently an increasing end of article. on coeliac disease therapeutic trials and issue recommendations for outcome measures. number of trials have begun to explore alternative treatment strategies. Correspondence to Design Based on a literature review of 10 062 Dr Jonas F Ludvigsson, references, we (17 researchers and 2 patient ► A large number of trials of non-dietary Department of Medical representatives from 10 countries) reviewed the use treatments for coeliac disease are ongoing or Epidemiology and Biostatistics, and suitability of both clinical and non-clinical outcome under way. -
Supplementary Data
Supplemental figures Supplemental figure 1: Tumor sample selection. A total of 98 thymic tumor specimens were stored in Memorial Sloan-Kettering Cancer Center tumor banks during the study period. 64 cases corresponded to previously untreated tumors, which were resected upfront after diagnosis. Adjuvant treatment was delivered in 7 patients (radiotherapy in 4 cases, cyclophosphamide- doxorubicin-vincristine (CAV) chemotherapy in 3 cases). 34 tumors were resected after induction treatment, consisting of chemotherapy in 16 patients (cyclophosphamide-doxorubicin- cisplatin (CAP) in 11 cases, cisplatin-etoposide (PE) in 3 cases, cisplatin-etoposide-ifosfamide (VIP) in 1 case, and cisplatin-docetaxel in 1 case), in radiotherapy (45 Gy) in 1 patient, and in sequential chemoradiation (CAP followed by a 45 Gy-radiotherapy) in 1 patient. Among these 34 patients, 6 received adjuvant radiotherapy. 1 Supplemental Figure 2: Amino acid alignments of KIT H697 in the human protein and related orthologs, using (A) the Homologene database (exons 14 and 15), and (B) the UCSC Genome Browser database (exon 14). Residue H697 is highlighted with red boxes. Both alignments indicate that residue H697 is highly conserved. 2 Supplemental Figure 3: Direct comparison of the genomic profiles of thymic squamous cell carcinomas (n=7) and lung primary squamous cell carcinomas (n=6). (A) Unsupervised clustering analysis. Gains are indicated in red, and losses in green, by genomic position along the 22 chromosomes. (B) Genomic profiles and recurrent copy number alterations in thymic carcinomas and lung squamous cell carcinomas. Gains are indicated in red, and losses in blue. 3 Supplemental Methods Mutational profiling The exonic regions of interest (NCBI Human Genome Build 36.1) were broken into amplicons of 500 bp or less, and specific primers were designed using Primer 3 (on the World Wide Web for general users and for biologist programmers (see Supplemental Table 2) [1]. -
Whole Exome Sequencing in Coloboma/Microphthalmia: Identification of Novel and Recurrent Variants in Seven Genes
G C A T T A C G G C A T genes Article Whole Exome Sequencing in Coloboma/Microphthalmia: Identification of Novel and Recurrent Variants in Seven Genes Patricia Haug 1 , Samuel Koller 1 , Jordi Maggi 1 , Elena Lang 1,2, Silke Feil 1, Agnès Wlodarczyk 1, Luzy Bähr 1, Katharina Steindl 3, Marianne Rohrbach 4 , Christina Gerth-Kahlert 2,† and Wolfgang Berger 1,5,6,*,† 1 Institute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland; [email protected] (P.H.); [email protected] (S.K.); [email protected] (J.M.); [email protected] (E.L.); [email protected] (S.F.); [email protected] (A.W.); [email protected] (L.B.) 2 Department of Ophthalmology, University Hospital and University of Zurich, 8091 Zurich, Switzerland; [email protected] 3 Institute of Medical Genetics, University of Zurich, 8952 Schlieren, Switzerland; [email protected] 4 Division of Metabolism and Children’s Research Centre, University Children’s Hospital Zurich, 8032 Zurich, Switzerland; [email protected] 5 Neuroscience Center Zurich (ZNZ), University and ETH Zurich, 8006 Zurich, Switzerland 6 Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8006 Zurich, Switzerland * Correspondence: [email protected] † Both authors contributed equally to this work. Abstract: Coloboma and microphthalmia (C/M) are related congenital eye malformations, which can cause significant visual impairment. Molecular diagnosis is challenging as the genes associated to date with C/M account for only a small percentage of cases. Overall, the genetic cause remains unknown in up to 80% of patients. -
A Small Molecule Promotes Cartilage Extracellular Matrix Generation and Inhibits Osteoarthritis Development
ARTICLE https://doi.org/10.1038/s41467-019-09839-x OPEN A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development Yuanyuan Shi1,2, Xiaoqing Hu1,2, Jin Cheng1, Xin Zhang1, Fengyuan Zhao1, Weili Shi1, Bo Ren1, Huilei Yu1, Peng Yang1, Zong Li1, Qiang Liu1, Zhenlong Liu 1, Xiaoning Duan1, Xin Fu1, Jiying Zhang1, Jianquan Wang1 & Yingfang Ao1 1234567890():,; Degradation of extracellular matrix (ECM) underlies loss of cartilage tissue in osteoarthritis, a common disease for which no effective disease-modifying therapy currently exists. Here we describe BNTA, a small molecule with ECM modulatory properties. BNTA promotes gen- eration of ECM components in cultured chondrocytes isolated from individuals with osteoarthritis. In human osteoarthritic cartilage explants, BNTA treatment stimulates expression of ECM components while suppressing inflammatory mediators. Intra-articular injection of BNTA delays the disease progression in a trauma-induced rat model of osteoarthritis. Furthermore, we identify superoxide dismutase 3 (SOD3) as a mediator of BNTA activity. BNTA induces SOD3 expression and superoxide anion elimination in osteoarthritic chondrocyte culture, and ectopic SOD3 expression recapitulates the effect of BNTA on ECM biosynthesis. These observations identify SOD3 as a relevant drug target, and BNTA as a potential therapeutic agent in osteoarthritis. 1 Institute of Sports Medicine, Beijing Key Laboratory of Sports Injuries, Peking University Third Hospital, 100191 Beijing, China. 2These authors contributed equally: Yuanyuan Shi, Xiaoqing Hu. Correspondence and requests for materials should be addressed to J.W. (email: [email protected]) or to Y.A. (email: [email protected]) NATURE COMMUNICATIONS | (2019) 10:1914 | https://doi.org/10.1038/s41467-019-09839-x | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09839-x steoarthritis (OA) is the most prevalent musculoskeletal compared with vehicle (Fig. -
A Common Dietary Component Wheat Amylase Trypsin Inhibitors As Drivers of Chronic Liver Disease in Pre-Clinical Models of NASH and Liver Fibrosis
A Common Dietary Component Wheat Amylase Trypsin Inhibitors as Drivers of Chronic Liver Disease in Pre-Clinical Models of NASH and Liver Fibrosis Muhammad Ashfaq-Khan1, Misbah Aslam1,2, Muhammad Asif Qureshi3, Marcel Senkowski1, Shih Yen-Weng1, Yong Ook Kim1, Jörn M. Schattenberg4, Detlef Schuppan*1,4 1Institute of Translational Immunology, University Medical Center, Mainz, Germany 2 Shaheed Benazir Bhutto Women University, Peshawar, Pakistan 3 Dow University Medical Sciences, Karachi, Pakistan 4 Division of Gastroenterology, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, US. BACKGROUND & AIMS Proinflammatory gene expressions and immunohistochemistry of epididymal fat LFD HFD The gut-liver-axis has emerged an important Weight base indices driver of chronic liver disease. In line with this, specific food derived (non-tolerable) immunogenic Poster presented at: presented Poster HFD/G/ATI HFD/ATI signals from the gut are potentially the important CLSs CD68+ contributors in worsening obesity and non- alcoholic fatty liver disease (NAFLD) and liver fibrosis. A common immunogenic component in food staple (that resist to intestinal degradation) are wheat amylase trypsin inhibitors (ATI) that activate intestinal macrophages and dendritic cells via toll like receptor-4 migrate and propagate the inflammatory stimulus to the peripheral organs such as liver. We therefore studied how far nutritional ATI would affect NAFLD and liver Non alcoholic steatohepatitis (NAS) score fibrosis in preclinical models of NASH and liver A HFD HFD/G/ATI HFD/ATI fibrosis. LFD DOI: 10.3252/pso.eu.ILC2019.2019 METHOD 20x . Male C57BI/6J mice received a carbohydrate and protein 40x (zein) defined low fat or high fat diet (HFD), with or without 30% of the protein being replaced by wheat E B LFD HFD gluten (G, naturally containing 0.15g ATI per 10g), or 0.7% of the zein as purified ATI for 8 weeks. -
Skeletal Muscle Transcriptome in Healthy Aging
ARTICLE https://doi.org/10.1038/s41467-021-22168-2 OPEN Skeletal muscle transcriptome in healthy aging Robert A. Tumasian III 1, Abhinav Harish1, Gautam Kundu1, Jen-Hao Yang1, Ceereena Ubaida-Mohien1, Marta Gonzalez-Freire1, Mary Kaileh1, Linda M. Zukley1, Chee W. Chia1, Alexey Lyashkov1, William H. Wood III1, ✉ Yulan Piao1, Christopher Coletta1, Jun Ding1, Myriam Gorospe1, Ranjan Sen1, Supriyo De1 & Luigi Ferrucci 1 Age-associated changes in gene expression in skeletal muscle of healthy individuals reflect accumulation of damage and compensatory adaptations to preserve tissue integrity. To characterize these changes, RNA was extracted and sequenced from muscle biopsies col- 1234567890():,; lected from 53 healthy individuals (22–83 years old) of the GESTALT study of the National Institute on Aging–NIH. Expression levels of 57,205 protein-coding and non-coding RNAs were studied as a function of aging by linear and negative binomial regression models. From both models, 1134 RNAs changed significantly with age. The most differentially abundant mRNAs encoded proteins implicated in several age-related processes, including cellular senescence, insulin signaling, and myogenesis. Specific mRNA isoforms that changed sig- nificantly with age in skeletal muscle were enriched for proteins involved in oxidative phosphorylation and adipogenesis. Our study establishes a detailed framework of the global transcriptome and mRNA isoforms that govern muscle damage and homeostasis with age. ✉ 1 National Institute on Aging–Intramural Research Program, National -
393LN V 393P 344SQ V 393P Probe Set Entrez Gene
393LN v 393P 344SQ v 393P Entrez fold fold probe set Gene Gene Symbol Gene cluster Gene Title p-value change p-value change chemokine (C-C motif) ligand 21b /// chemokine (C-C motif) ligand 21a /// chemokine (C-C motif) ligand 21c 1419426_s_at 18829 /// Ccl21b /// Ccl2 1 - up 393 LN only (leucine) 0.0047 9.199837 0.45212 6.847887 nuclear factor of activated T-cells, cytoplasmic, calcineurin- 1447085_s_at 18018 Nfatc1 1 - up 393 LN only dependent 1 0.009048 12.065 0.13718 4.81 RIKEN cDNA 1453647_at 78668 9530059J11Rik1 - up 393 LN only 9530059J11 gene 0.002208 5.482897 0.27642 3.45171 transient receptor potential cation channel, subfamily 1457164_at 277328 Trpa1 1 - up 393 LN only A, member 1 0.000111 9.180344 0.01771 3.048114 regulating synaptic membrane 1422809_at 116838 Rims2 1 - up 393 LN only exocytosis 2 0.001891 8.560424 0.13159 2.980501 glial cell line derived neurotrophic factor family receptor alpha 1433716_x_at 14586 Gfra2 1 - up 393 LN only 2 0.006868 30.88736 0.01066 2.811211 1446936_at --- --- 1 - up 393 LN only --- 0.007695 6.373955 0.11733 2.480287 zinc finger protein 1438742_at 320683 Zfp629 1 - up 393 LN only 629 0.002644 5.231855 0.38124 2.377016 phospholipase A2, 1426019_at 18786 Plaa 1 - up 393 LN only activating protein 0.008657 6.2364 0.12336 2.262117 1445314_at 14009 Etv1 1 - up 393 LN only ets variant gene 1 0.007224 3.643646 0.36434 2.01989 ciliary rootlet coiled- 1427338_at 230872 Crocc 1 - up 393 LN only coil, rootletin 0.002482 7.783242 0.49977 1.794171 expressed sequence 1436585_at 99463 BB182297 1 - up 393 -
Sensitivities to Wheat? Gluten Might Not Be to Blame
Recently published research suggests that there may be a previously unknown protein in wheat which may be causing the symptoms we have associated with gluten in the past: Amylase- Trypsin Inhibitors (ATIs). Sensitivities to Wheat? Gluten Might Not Be to Blame What you've heard about gluten might be wrong. This article originally appeared on Medical Daily. Gluten may not be the culprit when it comes to wheat sensitivities, according to a new body of research presented at the United European Gastroenterology Week 2016. Instead, a team of scientists from Johannes Gutenberg University in Germany discovered a different protein in wheat known as amylase-trypsin inhibitors (ATIs), which may be what triggers stomach- sickening inflammation and other symptoms. The whole grains/gluten situation and its potential impact on health issues appears to be developing much more complexity than was previously understood: recent research in Australia identified dozens of proteins in wheat that have previously not been known, and many of these may in fact be more detrimental than those that are typically tested for (and there are currently no lab tests available for these proteins). (We were unable to locate the published research for this Australian paper by our publishing deadline, but we will continue to search for it and hopefully include it in a future newsletter). Biotics offers a number of formulations targeted towards the GI system: A.D.P. (Anti-Dysbiosis Product) 60T Berberine HCl May help activate AMPK Bio-HPF CANADA (H-Pylori Factor) May help activate AMPK BioDoph-7 Plus BioDophilus Caps BioDophilus-FOS Bromelain Plus CLA Caprin 100C FC-Cidal GamOctaPro (Powder) Gastrazyme HCL-Plus IAG Intenzyme Forte (Trypsin & Alpha Chymotrypsin) IPS Canada (Intestinal Permeability Support) L-Glutamine Caps L-Glutamine Powder Lactozyme Irrespective of the specific proteins in wheat and other grains that cause health issues, we all know that grains in general and some specific grains in particular (wheat, rye and barley). -
The Constitutive Extracellular Protein Release by Acute Myeloid
cancers Article The Constitutive Extracellular Protein Release by Acute Myeloid Leukemia Cells—A Proteomic Study of Patient Heterogeneity and Its Modulation by Mesenchymal Stromal Cells Elise Aasebø 1,2 , Annette K. Brenner 1, Even Birkeland 2, Tor Henrik Anderson Tvedt 3, Frode Selheim 2, Frode S. Berven 2 and Øystein Bruserud 2,3,* 1 Department of Clinical Science, University of Bergen, 5021 Bergen, Norway; [email protected] (E.A.); [email protected] (A.K.B.) 2 The Proteomics Facility of the University of Bergen (PROBE), University of Bergen, 5009 Bergen, Norway; [email protected] (E.B.); [email protected] (F.S.); [email protected] (F.S.B.) 3 Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway; [email protected] * Correspondence: [email protected] or [email protected] Simple Summary: The formation of normal blood cells in the bone marrow is supported by a network of non-hematopoietic cells including connective tissue cells, blood vessel cells and bone-forming cells. These cell types support and regulate the growth of acute myeloid leukemia (AML) cells Citation: Aasebø, E.; Brenner, A.K.; and communicate with leukemic cells through the release of proteins to their common extracellular Birkeland, E.; Tvedt, T.H.A.; Selheim, F.; Berven, F.S.; Bruserud, Ø. The microenvironment. One of the AML-supporting normal cell types is a subset of connective tissue Constitutive Extracellular Protein cells called mesenchymal stem cells. In the present study, we observed that AML cells release a wide Release by Acute Myeloid Leukemia range of diverse proteins into their microenvironment, but patients differ both with regard to the Cells—A Proteomic Study of Patient number and amount of released proteins. -
Zedira Communication
Press release __________________________________________________________________________ Zedira, Dr. Falk Pharma and the University of Mainz Hospital, which together comprise a flagship project of the Ci3 leading-edge cluster, are to receive additional subsidy funding for clinical development of a celiac disease drug. __________________________________________________________________________ Darmstadt, Freiburg, Mainz 20 October 2015 The consortium consisting of Zedira, Dr. Falk Pharma and Prof. Schuppan of the Institute of Translational Immunology and the Department of Medicine at the Johannes Gutenberg University in Mainz has announced that their collaboration on drug development of celiac disease is being further supported under the Ci3 excellence cluster of the German Federal Ministry for Education and Research (German abbreviation: BMBF). The project involves the clinical development of the ZED1227 drug candidate. ZED1227 is the first low-molecular tissue transglutaminase blocker in the clinics. The joint venture was started as a flagship project of the leading-edge cluster for individualized immuneintervention (Ci3). Celiac Disease is the most common chronic inflammation of the small intestine, with a worldwide prevalence around 1% in most countries. The autoimmune disease is triggered and maintained by alimentary gluten in genetically susceptible individuals. About Zedira: The Darmstadt-based biotech company focuses on celiac disease and consequently also on the transglutaminase family of enzymes. The Company develops, produces and markets products for research and development as well as for diagnostics. Based on its patented family of low-molecular transglutaminase blockers, Zedira is establishing an active ingredient pipeline covering the primary indication of celiac disease. As an area of secondary indication the company is working on new approaches to thrombosis prophylaxis. Further, Zedira is working on bioavailable tissue transglutaminase inhibitors to address fibrotic diseases, e.g. -
The Genetics of Deafness in Domestic Animals
REVIEW published: 08 September 2015 doi: 10.3389/fvets.2015.00029 The genetics of deafness in domestic animals George M. Strain * Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USA Although deafness can be acquired throughout an animal’s life from a variety of causes, hereditary deafness, especially congenital hereditary deafness, is a significant problem in several species. Extensive reviews exist of the genetics of deafness in humans and mice, but not for deafness in domestic animals. Hereditary deafness in many species and breeds is associated with loci for white pigmentation, where the cochlear pathology is cochleo-saccular. In other cases, there is no pigmentation association and the cochlear pathology is neuroepithelial. Late onset hereditary deafness has recently been identi- fied in dogs and may be present but not yet recognized in other species. Few genes responsible for deafness have been identified in animals, but progress has been made Edited by: for identifying genes responsible for the associated pigmentation phenotypes. Across Edward E. Patterson, University of Minnesota College of species, the genes identified with deafness or white pigmentation patterns include MITF, Veterinary Medicine, USA PMEL, KIT, EDNRB, CDH23, TYR, and TRPM1 in dog, cat, horse, cow, pig, sheep, Reviewed by: ferret, mink, camelid, and rabbit. Multiple causative genes are present in some species. D. Colette Williams, Veterinary Medical Teaching Hospital Significant work remains in many cases to identify specific chromosomal deafness genes at the University of California Davis, so that DNA testing can be used to identify carriers of the mutated genes and thereby USA Dennis P.